Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: Fitting PBPK models to observed clinical data

British Journal of Clinical Pharmacology

Volumn 79, Issue 1, 2015, Pages 48-55

  Tsamandouras, Nikolaos ^a   Rostami Hodjegan, Amin ^a,b   Aarons, Leon ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CERTARA UK LIMITED   (United Kingdom)

Author keywords

Bayesian analysis; identifiability; middle out approach; parameter estimation; PBPK; population variability

Indexed keywords

ARTICLE; BAYES THEOREM; CLINICAL STUDY; COMPARTMENT MODEL; COMPUTER MODEL; EXPERIMENTAL DESIGN; IN VITRO STUDY; INTRINSIC CLEARANCE; NONBIOLOGICAL MODEL; PHARMACOKINETICS; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; POPULATION MODEL; BIOLOGICAL MODEL; HUMAN; INFORMATION RETRIEVAL;

BAYES THEOREM; HUMANS; INFORMATION STORAGE AND RETRIEVAL; MODELS, BIOLOGICAL; PHARMACOKINETICS;

EID: 84919681951     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12234     Document Type: Article

References (69)

1. Aarons L,. Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. Br J Clin Pharmacol 2005; 60: 581-583.
2. Jamei M, Dickinson GL, Rostami-Hodjegan A,. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 2009; 24: 53-75.
3. Nestorov I,. Whole body pharmacokinetic models. Clin Pharmacokinet 2003; 42: 883-908.
4. Nestorov I,. Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 2007; 3: 235-249.
5. Teorell T,. Kinetics of distribution of substances administered to the body. Arch Intern Pharmacodyn 1937; 57: 205-240.
6. Reddy MB, Yang RSH, Clewell HJ, Andersen ME, eds. Physiologically Based Pharmacokinetic Modeling: Science and Applications. Hoboken, NJ: John Wiley & Sons, Inc, 2005.
7. Thompson CM, Sonawane B, Barton HA, DeWoskin RS, Lipscomb JC, Schlosser P, Chiu WA, Krishnan K,. Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J Toxicol Environ Health B Crit Rev 2008; 11: 519-547.
8. Rowland M, Peck C, Tucker G,. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011; 51: 45-73.
9. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, Song P, Brar SS, Madabushi R, Wu TC, Booth BP, Rahman NA, Reynolds KS, Gil Berglund E, Lesko LJ, Huang SM,. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 2011; 89: 259-267.
10. Benowitz N, Forsyth FP, Melmon KL, Rowland M,. Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model. Clin Pharmacol Ther 1974; 16: 87-98.
11. Benowitz N, Forsyth RP, Melmon KL, Rowland M,. Lidocaine disposition kinetics in monkey and man. II. Effects of hemorrhage and sympathomimetic drug administration. Clin Pharmacol Ther 1974; 16: 99-109.
12. Rodgers T, Leahy D, Rowland M,. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005; 94: 1259-1276.
13. Rodgers T, Rowland M,. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006; 95: 1238-1257.
14. Rostami-Hodjegan A,. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther 2012; 92: 50-61.
15. Rostami-Hodjegan A, Tucker GT,. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007; 6: 140-148.
16. Houston JB, Galetin A,. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 2008; 9: 940-951.
17. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J,. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 2005; 313: 1254-1262.
18. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y,. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 2009; 328: 652-662.
19. Björkman S,. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 2005; 59: 691-704.
20. Johnson T, Rostami-Hodjegan A, Tucker G,. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006; 45: 931-956.
21. Darwich AS, Pade D, Ammori BJ, Jamei M, Ashcroft DM, Rostami-Hodjegan A,. A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution. J Pharm Pharmacol 2012; 64: 1008-1024.
22. Gertz M, Cartwright C, Hobbs M, Kenworthy K, Rowland M, Houston JB, Galetin A,. Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential. Pharm Res 2013; 30: 761-780.
23. Dahl SG, Aarons L, Gundert-Remy U, Karlsson MO, Schneider YJ, Steimer JL, Troconiz IF,. Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual framework. Basic Clin Pharmacol Toxicol 2009; 106: 2-12.
24. Valentin J,. Basic anatomical and physiological data for use in radiological protection: reference values: ICRP publication 89. Ann ICRP 2002; 32: 1-277.
25. Davies B, Morris T,. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
26. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP,. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 1997; 13: 407-484.
27. Jamei M, Marciniak S, Edwards D, Wragg K, Feng K, Barnett A, Rostami-Hodjegan A,. The simcyp population based simulator: architecture, implementation, and quality assurance. In Silico Pharmacol 2013; 1: 9.
28. Bellman R, Åström KJ,. On structural identifiability. Math Biosci 1970; 7: 329-339.
29. Cobelli C, DiStefano JJ,. Parameter and structural identifiability concepts and ambiguities: a critical review and analysis. Am J Physiol 1980; 239: R7-R24.
30. Slob W, Janssen PHM, van den Hof JM,. Structural identifiability of PBPK models: practical consequences for modeling strategies and study designs. Crit Rev Toxicol 1997; 27: 261-272.
31. Yates J,. Structural identifiability of physiologically based pharmacokinetic models. J Pharmacokinet Pharmacodyn 2006; 33: 421-439.
32. Godfrey KR, Jones RP, Brown RF,. Identifiable pharmacokinetic models: the role of extra inputs and measurements. J Pharmacokinet Pharmacodyn 1980; 8: 633-648.
33. Gelman A, Bois F, Jiang J,. Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J Am Stat Assoc 1996; 91: 1400-1412.
34. Hengl S, Kreutz C, Timmer J, Maiwald T,. Data-based identifiability analysis of non-linear dynamical models. Bioinformatics 2007; 23: 2612-2618.
35. Gueorguieva I, Aarons L, Ogungbenro K, Jorga K, Rodgers T, Rowland M,. Optimal design for multivariate response pharmacokinetic models. J Pharmacokinet Pharmacodyn 2006; 33: 97-124.
36. Saltateli A, Chan K, Scott EM, eds. Sensivity Analysis. Hoboken, NJ: John Willey & Sons, Inc., 2000.
37. Nestorov I, Aarons L, Rowland M,. Physiologically based pharmacokinetic modeling of a homologous series of barbiturates in the rat: a sensitivity analysis. J Pharmacokinet Biopharm 1997; 25: 413-447.
38. Gueorguieva I, Nestorov I, Rowland M,. Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: diazepam case study. J Pharmacokinet Pharmacodyn 2006; 33: 1-27.
39. Woodruff TJ, Bois FY,. Optimization issues in physiological toxicokinetic modeling: a case study with benzene. Toxicol Lett 1993; 69: 181-196.
40. Goldberg DE,. Genetic Algorithms in Search, Optimization and Machine Learning. Boston, MA: Addison-Wesley Publishing Co., Inc., 1989.
41. Yang J, Jamei M, Heydari A, Yeo KR, de la Torre R, Farré M, Tucker GT, Rostami-Hodjegan A,. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol 2006; 20: 842-849.
42. Peters SA,. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles. Clin Pharmacokinet 2008; 47: 245-259.
43. Jonsson F, Bois FY, Johanson G,. Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects. Arch Toxicol 2001; 75: 189-199.
44. Bernillon P, Bois FY,. Statistical issues in toxicokinetic modeling: a Bayesian perspective. Environ Health Perspect 2000; 108: (Suppl. 5): 883-893.
45. Smith AE, Evans JS,. Uncertainty in fitted estimates of apparent in vivo metabolic constants for chloroform. Fundam Appl Toxicol 1995; 25: 29-44.
46. Gill KL, Gertz M, Houston JB, Galetin A,. Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data. Drug Metab Dispos 2013; 41: 744-753.
47. Pertinez H, Chenel M, Aarons L,. A physiologically based pharmacokinetic model for strontium exposure in rat. Pharm Res 2013; 30: 1536-1552.
48. Nestorov I,. Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. Toxicol Lett 2001; 120: 411-420.
49. Bois FY, Jamei M, Clewell HJ,. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology 2010; 278: 256-267.
50. Ette EI, Williams PJ,. Population pharmacokinetics ii: estimation methods. Ann Pharmacother 2004; 38: 1907-1915.
51. Sheiner L, Beal S,. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1980; 8: 553-571.
52. Sheiner L, Beal S,. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 1981; 9: 635-651.
53. Wakefield JC, Smith AFM, Racine-Poon A, Gelfand AE,. Bayesian analysis of linear and non-linear population models by using the Gibbs sampler. J R Stat Soc Ser C Appl Stat 1994; 43: 201-221.
54. Wakefield J,. The Bayesian analysis of population pharmacokinetic models. J Am Stat Assoc 1996; 91: 62-75.
55. Bois FY,. Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. Environ Health Perspect 2000; 108: (Suppl. 2): 307-316.
56. Gueorguieva I, Aarons L, Rowland M,. Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in winbugs. J Pharmacokinet Pharmacodyn 2006; 33: 571-594.
57. Yang Y, Xu X, Georgopoulos PG,. A Bayesian population PBPK model for multiroute chloroform exposure. J Expo Sci Environ Epidemiol 2010; 20: 326-341.
58. Krauss M, Burghaus R, Lippert J, Niemi M, Neuvonen P, Schuppert A, Willmann S, Kuepfer L, Gorlitz L,. Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification. In Silico Pharmacol 2013; 1: 6.
59. Langdon G, Gueorguieva I, Aarons L, Karlsson M,. Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM. Eur J Clin Pharmacol 2007; 63: 485-498.
60. Gibiansky L, Gibiansky E, Bauer R,. Comparison of nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model. J Pharmacokinet Pharmacodyn 2012; 39: 17-35.
61. Gisleskog PO, Karlsson MO, Beal SL,. Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn 2002; 29: 473-505.
62. Okino MS, Mavrovouniotis ML,. Simplification of mathematical models of chemical reaction systems. Chem Rev 1998; 98: 391-408.
63. Nestorov IA, Aarons LJ, Arundel PA, Rowland M,. Lumping of whole-body physiologically based pharmacokinetic models. J Pharmacokinet Biopharm 1998; 26: 21-46.
64. Brochot C, Tõth J, Bois FY,. Lumping in pharmacokinetics. J Pharmacokinet Pharmacodyn 2005; 32: 719-736.
65. Pilari S, Huisinga W,. Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models. J Pharmacokinet Pharmacodyn 2010; 37: 365-405.
66. Dokoumetzidis A,. Lumping of compartments. PAGE 21 2012; Abstr 2637. Available at http://www.page-meeting.org/?abstract=2637 (last accessed 7 May 2013).
67. Dokoumetzidis A, Aarons L,. A method for robust model order reduction in pharmacokinetics. J Pharmacokinet Pharmacodyn 2009; 36: 613-628.
68. Quinney SK, Zhang X, Lucksiri A, Gorski JC, Li L, Hall SD,. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos 2010; 38: 241-248.
69. Cao Y, Jusko W,. Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn 2012; 39: 711-723.